Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
2022 | Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial | El-Khoueiry, Anthony B; Meyer, Tim; ANN-LII CHENG ; Rimassa, Lorenza; Sen, Suvajit; Milwee, Steven; Kelley, Robin Kate; Abou-Alfa, Ghassan K | BMC cancer | 8 | 9 | |
2021 | Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT | Okusaka T.; Ikeda K.; Kudo M.; Finn R.; Qin S.; Han K.-H.; ANN-LII CHENG ; Piscaglia F.; Kobayashi M.; Sung M.; Chen M.; Wyrwicz L.; Yoon J.-H.; Ren Z.; Mody K.; Dutcus C.; Tamai T.; Ren M.; Hayato S.; Kumada H. | Journal of Gastroenterology | 7 | 7 | |
2009 | Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study | Faivre S.; Raymond E.; Boucher E.; Douillard J.; Lim H.Y.; Kim J.S.; Zappa M.; Lanzalone S.; Lin X.; DePrimo S.; Harmon C.; Ruiz-Garcia A.; Lechuga M.J.; ANN-LII CHENG | The Lancet Oncology | 257 | 232 | |
2015 | Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study | ANN-LII CHENG ; Kang Y.-K.; He A.R.; Lim H.Y.; Ryoo B.-Y.; Hung C.-H.; Sheen I.-S.; Izumi N.; Austin T.; Wang Q.; Greenberg J.; Shiratori S.; Beckman R.A.; Kudo M. | Journal of Hepatology | 39 | 42 | |
2021 | Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study | Kelley, Robin Kate; Sangro, Bruno; Harris, William; Ikeda, Masafumi; Okusaka, Takuji; Kang, Yoon-Koo; Qin, Shukui; Tai, David W-M; Lim, Ho Yeong; Yau, Thomas; Yong, Wei-Peng; ANN-LII CHENG ; Gasbarrini, Antonio; Damian, Silvia; Bruix, Jordi; Borad, Mitesh; Bendell, Johanna; Kim, Tae-You; Standifer, Nathan; He, Philip; Makowsky, Mallory; Negro, Alejandra; Kudo, Masatoshi; Abou-Alfa, Ghassan K | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 237 | 215 | |
2023 | Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma | BANG-BIN CHEN ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH ; TSUNG-HAO LIU ; YING-CHUN SHEN ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | European radiology | 17 | 13 | |
2020 | Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial | Kelley R.K.; Ryoo B.-Y.; Merle P.; Park J.-W.; Bolondi L.; Chan S.L.; Lim H.Y.; Baron A.D.; Parnis F.; Knox J.; Cattan S.; Yau T.; Lougheed J.C.; Milwee S.; El-Khoueiry A.B.; ANN-LII CHENG ; Meyer T.; Abou-Alfa G.K. | ESMO open | 46 | 46 | |
2023 | Selective inhibition of HDAC6 promotes bladder cancer radiosensitization and mitigates the radiation-induced CXCL1 signalling | YU-CHIEH TSAI ; Wang, Tzu-Yin; Hsu, Chia-Lang; WEI-CHOU LIN ; Chen, Jyun-Yu; Li, Jia-Hua; YEONG-SHIAU PU ; ANN-LII CHENG ; CHIA-HSIEN CHENG ; SHENG-FANG SU | British journal of cancer | 4 | 4 | |
2020 | Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma | Kelley R.K.; Meyer T.; Rimassa L.; Merle P.; Park J.-W.; Yau T.; Chan S.L.; Blanc J.-F.; Tam V.C.; Tran A.; Dadduzio V.; Markby D.W.; Kaldate R.; ANN-LII CHENG ; El-Khoueiry A.B.; Abou-Alfa G.K. | Clinical Cancer Research | 54 | 44 | |
2012 | Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy | YU-YUN SHAO ; Huang C.-C.; Lin S.-D.; CHIH-HUNG HSU ; ANN-LII CHENG | Clinical Cancer Research | 39 | 37 | |
2011 | Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; HSIANG-PO HUANG ; Huang J.-W.; PEI-JER CHEN ; Chen K.-F. | Journal of Hepatology | 146 | 140 | |
2010 | Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC | ZHONG-ZHE LIN ; YUNG-MING JENG ; Hu F.-C.; Pan H.-W.; Tsao H.-W.; Lai P.; PO-HUANG LEE ; ANN-LII CHENG ; Hsu H.-C. | BMC Cancer | 101 | 98 | |
1999 | The significance of body weight change in non-Hodgkins lymphoma | Chin Y.H.; Liu J.M.; Tai J.J.; Chuang M.S.; Ho Y.L.; Chen Y.M.; Whang-Peng J.; ANN-LII CHENG | Anticancer Research | 4 | 3 | |
2005 | Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: Implications from age-period-cohort analysis | Ying-Chun Shen ; Chang C.-J.; CHIUN HSU ; Cheng C.-C.; Chiu C.-F.; ANN-LII CHENG | Cancer Epidemiology Biomarkers and Prevention | 127 | 116 | |
2022 | A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma | WEI-WU CHEN ; CHIA-LANG HSU ; RUEY-LONG HONG ; JEN-CHIEH LEE ; Chang, Koping; CHIH-WEI YU ; Chen, San-Chi; JHE-CYUAN GUO ; Chen, Mei-Lu; Hsu, Meng-Chi; Kung, Ting-Fang; ANN-LII CHENG ; Yen, Chueh-Chuan | Clinical cancer research : an official journal of the American Association for Cancer Research | 6 | 6 | |
1995 | Single-step direct cloning of PCR products | Chuang S.-E.; Wang K.-C.; ANN-LII CHENG | Trends in Genetics | 4 | 2 | |
2021 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma | Greten T.F.; Abou-Alfa G.K.; ANN-LII CHENG ; Duffy A.G.; El-Khoueiry A.B.; Finn R.S.; Galle P.R.; Goyal L.; He A.R.; Kaseb A.O.; Kelley R.K.; Lencioni R.; Lujambio A.; Mabry Hrones D.; Pinato D.J.; Sangro B.; Troisi R.I.; Wilson Woods A.; Yau T.; Zhu A.X.; Melero I. | Journal for ImmunoTherapy of Cancer | 39 | 34 | |
2022 | Soft tissue sarcoma incidences and clinical characteristics are significantly different in France and Taiwan | WEI-WU CHEN ; Chiang, Ruru Chun-Ju; Le Cesne, Alex; Hsieh, Yu-Chun; Italiano, Antoine; Yang, Ya-Wen; Penel, Nicolas; WEN-CHUNG LEE ; Bompas, Emmanuelle; Valentin, Thibaud; Anract, Philippe; Firmin, Nelly; Duffaud, Florence; ANN-LII CHENG ; Ducimetiere, Francoise; KIN-WEI CHAN ; Blay, Jean-Yves | Cancer | 3 | 2 | |
2005 | Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung | KUN-HUEI YEH ; Shiou-Hwei Yeh ; Wan J.-P.; Ying-Chun Shen ; ANN-LII CHENG | Anti-Cancer Drugs | 4 | 3 | |
2015 | Sonic Hedgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinoma | CHIAO-LING TSAI ; Feng-Ming Hsu ; KAI-YUAN TZEN ; Liu W.-L.; ANN-LII CHENG ; CHIA-HSIEN CHENG | Journal of Gastroenterology and Hepatology (Australia) | 27 | 28 | |